Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (frα)–targeting Antibody-Drug Conjugate, in Combination with Carboplatin and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer
GYNECOLOGIC ONCOLOGY（2024）
关键词
Antibody-drug conjugate,Mirvetuximab soravtansine,Folate receptor alpha,Platinum-sensitive ovarian cancer,Combination therapy,Clinical trial
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要